The hollow fibre model - facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare

  • Authors:
    • Marie Suggitt
    • Patricia A. Cooper
    • Steven D. Shnyder
    • Michael C. Bibby
  • View Affiliations

  • Published online on: December 1, 2006     https://doi.org/10.3892/ijo.29.6.1493
  • Pages: 1493-1499
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

We describe a modified hollow fibre assay (HFA) for investigating the potential of novel molecules as pharmaceutical agents. In particular the assay provides drug/target interaction data that can facilitate the selection of lead compounds for further evaluation in more sophisticated solid tumour models, whilst successfully implementing the 3Rs - the ‘replacement’ ‘refinement’ and ‘reduction’ of animals. This more ethical and rapid approach to early drug development does not compromise on the validity, sensitivity, predictivity or efficacy of preclinical evaluation. We present novel data using the standard cross-linker mitomycin C (MMC) as a positive control, and two investigational DNA interactive molecules (C1311/ SJG-136). Tumour cells were seeded in fibres and implanted into mice. Following treatment with an intraperitoneal injection, fibres were excised and cells retrieved for pharmacodynamic analysis using the comet assay/fluorescence microscopy. Microscopy results revealed nuclear uptake and localisation within cytoplasmic organelles of HT29 colorectal adenocarcinoma cells following treatment with C1311 (150 mg/kg). Following treatment with SJG-136 (0.3 mg/kg) a 27.3% (p<0.001) DNA cross-linking (s.c.) effect was observed in the HL60 acute promyelocytic leukaemia cell line. DNA cross-linking effects of 55% (i.p) and 50% (s.c.) (p<0.005) were observed in the A549 lung carcinoma cell line following administration of MMC (6 mg/kg). These data are consistent with previous activity defined using solid tumour models, and support the use of the HFA for in vivo pharmacodynamic investigation whilst significantly reducing animal numbers and the influence of tumour growth on the welfare of mice.

Related Articles

Journal Cover

December 2006
Volume 29 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Suggitt M, Cooper PA, Shnyder SD and Bibby MC: The hollow fibre model - facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare. Int J Oncol 29: 1493-1499, 2006
APA
Suggitt, M., Cooper, P.A., Shnyder, S.D., & Bibby, M.C. (2006). The hollow fibre model - facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare. International Journal of Oncology, 29, 1493-1499. https://doi.org/10.3892/ijo.29.6.1493
MLA
Suggitt, M., Cooper, P. A., Shnyder, S. D., Bibby, M. C."The hollow fibre model - facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare". International Journal of Oncology 29.6 (2006): 1493-1499.
Chicago
Suggitt, M., Cooper, P. A., Shnyder, S. D., Bibby, M. C."The hollow fibre model - facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare". International Journal of Oncology 29, no. 6 (2006): 1493-1499. https://doi.org/10.3892/ijo.29.6.1493